You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
博瑞醫藥(688166.SH):BGM0504注射液治療非糖尿病的超重或肥胖的Ⅱ期臨牀試驗達成預期目標
格隆匯 10-13 15:43

格隆匯10月13日丨博瑞醫藥(688166.SH)公佈,公司全資子公司博瑞新創生物醫藥科技(無錫)有限公司(簡稱“博瑞新創”)自主研發的BGM0504注射液治療非糖尿病的超重或肥胖的Ⅱ期臨牀試驗達成預期目標。

BGM0504注射液治療超重或肥胖的II期臨牀試驗初步結果顯示,BGM0504注射液5mg、10mg、15mg劑量組受試者,每週給藥1次、給藥26~30周後的整體耐受性、安全性良好,各劑量組受試者在體重、腰圍等核心減重指標方面均明顯優於安慰劑組(p<0.0001);以及各劑量組受試者在次要療評指標方面,如心血管代謝風險指標、增加胰島素敏感性的相關指標、患者結局報吿指標等較基線均有改善,且優於安慰劑組。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account